WALTHAM, Mass. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals , Inc. (NASDAQ: AMAG) today announced that Scott Myers , Chief Executive Officer, and Brian Piekos , Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright 22 nd Annual Global Investment Conference More >

Financial guidance reissued to include EBITDA-positive projection for second-half 2020 Strategic shift and momentum build through recent business development activities Brian Piekos promoted to Chief Financial Officer Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass. , Aug. More >

WALTHAM, Mass. , July 28, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 More >

Vyleesi® returned to Palatin Technologies Company focuses on optimizing marketed assets and development of its innovative pipeline WALTHAM, Mass. , July 27, 2020 (GLOBE NEWSWIRE) --   AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced AMAG and Palatin Technologies, Inc. More >

Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties   Collaboration further advances the development of ciraparantag WALTHAM, Mass. More >

Data from two Phase 2 randomized, placebo-controlled, dose-ranging studies using ciraparantag demonstrate efficacy and safety in the reversal of apixaban and rivaroxaban WALTHAM, Mass. , July 12, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the poster More >

Company initiates CFO & COO succession plan; appoints internal seasoned finance leader as interim CFO Anthony Casciano assumes expanded role as AMAG’s COO WALTHAM, Mass. , June 11, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Edward (Ted) Myles , Chief More >

WALTHAM, Mass. , May 27, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals , Inc. (NASDAQ: AMAG) today announced that management will participate at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:00 p.m. Eastern Time . A live audio webcast of the virtual event will More >

Transaction allows AMAG to advance its strategic focus on Feraheme, Makena and its pipeline, consistent with previously announced plans Millicent Pharma uniquely positioned to drive revenue growth of Intrarosa WALTHAM, Mass. , May 21, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. More >

Feraheme ® (ferumoxytol injection) posts strong first quarter results Company implements a workforce reduction of approximately 30 percent or 140 positions, as part of a planned decrease in operating expenses Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass. More >

WALTHAM, Mass. , April 28, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its Board of Directors has appointed Scott Myers as AMAG’s President and Chief Executive Officer, and member of the Board, effective immediately. Mr. More >

WALTHAM, Mass. , April 27, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its first quarter 2020 financial results will be released on Monday, May 11, 2020 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 More >

WALTHAM, Mass. , April 16, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today provided an update regarding the potential impact of COVID-19 on the company. AMAG is committed to the health and safety of its employees, patients, healthcare providers, business partners and More >

Conference call scheduled for 8:00 a.m. EST today WALTHAM, Mass. , March 04, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2019 . More >

WALTHAM, Mass. , March 04, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced changes to its medical development organization. Effective March 31, 2020 , Julie Krop , M.D., Executive Vice President and Chief Medical Officer, will be leaving the Company. More >

WALTHAM, Mass. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its fourth quarter and full year 2019 financial results will be released on Wednesday, March 4, 2020 before the U.S. financial markets open. More >

WALTHAM, Mass. , Feb. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals , Inc. (NASDAQ: AMAG) today announced that management will participate in the following investor conferences: SVB Leerink 9 th Annual Global Healthcare Conference Wednesday, February 26, 2020 at 2:30 pm EST Location: New York, More >

Initiating CEO transition plan Divesting Intrarosa ® and Vyleesi ®  2020 financial guidance reflects reduction in annual operating expenses of more than  $100M and a return to positive adjusted EBITDA WALTHAM, Mass. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. More >

WALTHAM, Mass. , Jan. 03, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present at the 38 th  Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 9:30 a.m. Pacific Time ( 12:30 p.m. More >